TABLE 3.
Univariate Analyses for Factors Associated Initial Endocrine Remission, Durable Endocrine Remission, and Postremission Biochemical Recurrence After SRS for Acromegaly
| Factor | Initial remission P-value | Durable remission P-value | Recurrence after remission P-value |
|---|---|---|---|
| Age | .59 | .89 | .59 |
| Gender | .12 | .26 | .93 |
| Prior surgical resection | .03 | .02 | .10 |
| Random serum GH level prior to SRS | .0004 | .0004 | .07 |
| Serum IGF-1 level prior to SRS | <.0001 | <.0001 | .57 |
| Cessation of medication prior to SRS | .04 | .04 | .54 |
| Tumor volume | .09 | .07 | .24 |
| Whole sella targeted by SRS | .02 | .049 | .80 |
| SRS margin dose | .01 | .0007 | .0005 |
| SRS maximum dose | .0006 | <.0001 | <.0001 |
GH, growth hormone; IGF-1, insulin-like growth factor-1. Bold values are statistically significant (P < .05).